Network Reconfiguration Among Cerebellar Visual, and Motor Regions Affects Movement Function in Spinocerebellar Ataxia Type 3

• DOI: 10.3389/fnagi.2022.773119
• Publication Date: 2022-04-11T07:26:52Z
• Authors: Hui Chen; Limeng Dai; Yuhan Zhang; Liu Feng; Zhenzhen Jiang; Xingang Wang; Dongjing Xie; Jing Guo; Huafu Chen; Jian Wang; Chen Liu
• Keywords: Cuneus; Lingual gyrus; Clustering coefficient

Spinocerebellar ataxia type 3 (SCA3) is a rare movement disorder characterized with ataxia. Previous studies on disorders show that the whole-brain functional network tends to be more regular, and these reconfigurations correlate genetic clinical variables.To test whether brain in patients SCA3 follows similar reconfiguration course other disorders, we recruited 41 (mean age = 40.51 ± 12.13 years; 23 male) sex-matched healthy individuals (age 40.10 11.56 24 male). In both groups, topology of resting-state magnetic resonance imaging (rs-fMRI) was conducted using graph theory, relationships among topologies, cytosine-adenine-guanine (CAG) repeats, symptoms, connectivity were explored partial correlation analysis, controlling for sex.The networks tended regular higher clustering coefficient, local efficiency, modularity SCA3. Hubs reorganized as number hubs increased motor-related areas decreased cognitive areas. At global level, small-worldness normalized coefficients significantly positively correlated motor symptoms. nodal coefficient efficiency visual (bilateral cuneus) sensorimotor (right cerebellar lobules IV, V, VI) middle frontal gyrus). The bilateral cuneus gyrus negatively between right caudate nucleus calcarine disease duration, while posterior cingulum left lobule III, inferior occipital IX correlated.Our results demonstrate occurred patients, visual-related regions, such as, gyrus, forayed neighbor nodes "resource predators" compensate normal function, function having priority comparing high-order functions. This study provides new information about neurological mechanisms underlying impairments resting state, which give potential guideline future treatments.[www.ClinicalTrials.gov], identifier [ChiCTR1800019901].